All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2019-06-05T18:07:46.000Z

ASCO 2019 | How should hypomethylating agents be used in combination therapy?

By Joanna Nikitorowicz-Buniak, Zara Kassam
Featured
Aref Al-Kali
Jun 5, 2019
Share:

Bookmark this article

Aref Al-Kali from the Mayo Clinic, Rochester, US, speaks with the AML Global Portal (AGP) during ASCO 2019 about how to optimize the use of hypomethylating agents in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Aref Al-Kali raises many questions within the topic, including whether azacitidine and decitabine should be used as single agents, or in combination with newer agents such as venetoclax. One particular topic that was of interest to the ASCO audience during Aref Al-Kali's talk during ASCO, was how to use fewer drugs, such as low dose azacitidine or decitabine, in patients with low-risk MDS.

How should hypomethylating agents be used in combination therapy?

More about...
ASCO 2019AzacitidineDecitabineVenetoclax

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 2 days left ...

Related articles

Add bookmark

AML World Awareness Day 2020 | Clinical trials involving novel agents in AML

On April 21, 2020, communities will unite on Acute Myeloid Leukemia (AML) World Awareness Day (WAD) to raise awareness of AML. Both scientific and patient communities will...

Apr 20, 2020
Add bookmark

AML World Awareness Day 2020 | Clinical trials involving novel agents in AML

On April 21, 2020, communities will unite on Acute Myeloid Leukemia (AML) World Awareness Day (WAD) to raise awareness of...

Apr 20, 2020
Add bookmark

Correlation of responses to venetoclax combination treatment and AML mutations or BCL-2 expression

Results from an exploratory biomarker analysis from two phase Ib/II studies that examined the combination of venetoclax with HMA or LDAC in older...

Jan 15, 2020
Add bookmark

Correlation of responses to venetoclax combination treatment and AML mutations or BCL-2 expression

Results from an exploratory biomarker analysis from two phase Ib/II studies that examined the...

Jan 15, 2020

Newsletter

Subscribe to get the best content related to AML delivered to your inbox